A patient undergoing Valeda Light Therapy Treatment for dry AMD.
About Valeda Light Therapy Treatment
The Valeda Light Delivery System (VLDS) is the first and only FDA-authorized treatment for intermediate dry age-related macular degeneration (AMD). This non-invasive approach specifically targets mitochondrial dysfunction in the retina, a key factor of dry AMD, to improve visual acuity, reduce drusen volume, and prevent geographic atrophy.
Using photobiomodulation (PBM), Valeda delivers specific wavelengths of red and infrared light to the eyes to help stimulate cellular energy production and improve cellular health. Patients typically undergo a series of 9 treatment sessions over 3-5 weeks, with follow-up cycles every 4 months. Most recipients tolerate the procedure well and experience no pain.
Candidates for Valeda Light Therapy
Valeda is ideal for patients with dry AMD characterized by the presence of drusen or non-central geographic atrophy. The treatment is not suitable for individuals with wet AMD or those experiencing significant vision loss due to central macular atrophy.
